More than 70 per cent of drugmakers believe serialization requirements in the US will positively transform their business processes, according to a new report.

Commissioned by consultancy KPMG, the report involved a survey of leading organisations within the pharmaceutical industry – including branded pharma, generics, distributors and virtual manufacturers – looking at their degree of readiness to meet the new US anti-counterfeiting serialization requirements introduced later this year.

To continue reading, Click Here